Role of standard antibiotic therapy in Helicobacter pylori associated diseases of stomach in development of stomach MALT lymphoma

Background: Helicobacter pylori is an established cause of gastritis and has been implicated in extradigestive diseases. Objective: To investigate the role of H. pylori in patients with unexplained refractory pruritus. Methods: Ten patients with severe pruritus unresponsive to conventional therapy were evaluated for active H. pylori infection by H. pylori serology followed by either esophagogastroduodenoscopy (EGD) or urea breath test. Of the 10 patients, 8 were found to have active infection. All 10 received anti- H. pylori antibiotic therapy and were reevaluated for relief of pruritus. Results: Of 8 patients with active H. pylori infection, 87.5% (7/8) had some type of pruritus relief after triple therapy. Of these, 62.5% (5/8) had complete relief and 25% (2/8) had temporary relief of pruritus. The remaining 12.5% (1/8) did not respond. Two control patients without active H. pylori infection had no relief of pruritus with therapy. Conclusions: We have identified a population of patients with refractory pruritus and active H. pylori infection whose pruritus resolved after eradication of H. pylori.

Download Full-text

THE ROLE OF PROBIOTICS IN THE TREATMENT OF HELICOBACTER PYLORI ASSOCIATED DISEASES

Medical Council ◽

10.21518/2079-701x-2017-5-80-84 ◽

2017 ◽

pp. 80-84

Author(s):

E. Y. Plotnikova ◽

T. Y. Gracheva

Keyword(s):

Helicobacter Pylori ◽

Associated Diseases

Download Full-text

Sa1888 Critical Role of Toll Like Receptor 4 Subtype in Helicobacter pylori Induced Gastritis and MALT Lymphoma

Gastroenterology ◽

10.1016/s0016-5085(13)61198-1 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-328

Author(s):

Romy Kaebisch ◽

Markus Gerhard ◽

Christian Prinz

Keyword(s):

Helicobacter Pylori ◽

Malt Lymphoma ◽

Critical Role ◽

Toll Like Receptor ◽

Toll Like Receptor 4

Download Full-text

PURULENT SEPTIC COMPLICATIONS OF ACUTE PANCREATITIS AND THEIR PATHOGENETIC RELATIONSHIP WITH HELICOBACTER PYLORI

Novosti Khirurgii ◽

10.18484/2305-0047.2021.5.542 ◽

2021 ◽

Vol 29 (5) ◽

pp. 542-548

Author(s):

I.V. Kolosovych ◽

◽

I.V. Hanol ◽

Keyword(s):

Acute Pancreatitis ◽

Helicobacter Pylori ◽

Antibiotic Therapy ◽

Positive Result ◽

Comparison Group ◽

Main Group ◽

Immunoglobulin M ◽

Septic Complications ◽

Bacteriological Study

Objective. To study of the role of Helicobacter pylori as an etiological factor of acute pancreatitis and a marker of the development of its purulent-septic complications. Мethods. The study was conducted in the period of 2015-2020; patients with acute pancreatitis (n=124) were divided into 2 groups: the main group (66 patients with moderate severity and severe course) and the comparison group (58 patients with a mild form). All patients underwent a screening study of Helicobacter pylori in feces and serological blood test to detect antibodies, namely immunoglobulin M to Helicobacter pylori (determination of the phase of the disease - acute or chronic). In 39 (31.5%) patients of the main group, a bacteriological study of biological and biopsyspecimensof antral mucous membrane were taken and examined histologically for organisms. The selection of antibiotics for treatment was carried out taking into account the infection of patients with Helicobacter pylori and was performed using the author’s method, the effectiveness of treatment was controlled microbiologically. Results. The positive result of the express test was in 66 (100%) patients of the main group and in 39 (67.2%) patients in the comparison group. During serological examination, a positive result was obtained: 24 hours after hospitalization - in 8 (13.8%) patients in the comparison group, in 23 (34.8%) patients in the main group; after 7 days - in 9 (15.5%) patients and 42 (63.3%) patients, respectively. Helicobacter pylori is sensitive to the majority of antibiotics used to treat purulent-septic complications of acute pancreatitis; after finishing the course of antibiotic therapy, eradication was achieved in 37 (94.9%) patients of the main group. Conclusion. Positive results of a serological study of Нelicobacter pylori after 7 days from the moment of hospitalization were more common in patients of the main group (63.3%) in relation to the comparison group (15.5%) (χ<sup>2</sup>=28.9, p<0.001), which gives grounds to consider bacteria, as one of the markers of the development of purulent-septic complications of acute pancreatitis. What this paper adds The role of Helicobacter pylori (HP) in the pathogenesis of acute pancreatitis has been studied for the first time and its value as a marker for septic complications development of acute pancreatitis is shown. It allowed optimizing the etiotropic antibiotic therapy for this disease.

Download Full-text

Frontline antibiotic therapy for early‐stage Helicobacter pylori ‐negative gastric MALT lymphoma

American Journal of Hematology ◽

10.1002/ajh.25447 ◽

2019 ◽

Vol 94 (6) ◽

pp. E150-E153

Author(s):

Paolo Strati ◽

Seung Tae Lee ◽

Purnima Teegavarupu ◽

Anusha Karri ◽

Saswatha Anireddy ◽

...

Keyword(s):

Helicobacter Pylori ◽

Antibiotic Therapy ◽

Malt Lymphoma ◽

Early Stage ◽

Gastric Malt Lymphoma

Download Full-text

Is mucosa‑associated lymphoid tissue lymphoma an infectious disease? Role of Helicobacter�pylori and eradication antibiotic therapy (Review)

Experimental and Therapeutic Medicine ◽

10.3892/etm.2020.9031 ◽

2020 ◽

Author(s):

Cătălina Vlăduţ ◽

Mihai Cioc�rlan ◽

Raluca Costache ◽

Mariana Jinga ◽

Vasile Balaban ◽

...

Keyword(s):

Infectious Disease ◽

Helicobacter Pylori ◽

Antibiotic Therapy ◽

Lymphoid Tissue

Download Full-text

Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature

Blood ◽

10.1182/blood-2013-02-486522 ◽

2013 ◽

Vol 122 (8) ◽

pp. 1350-1357 ◽

Cited By ~ 52

Author(s):

Barbara Kiesewetter ◽

Markus Raderer

Keyword(s):

Antibiotic Therapy ◽

Malt Lymphoma ◽

Large Scale ◽

Progressive Disease ◽

Standard Of Care ◽

Manual Search ◽

First Line Therapy ◽

Therapeutic Trials

AbstractAlthough antibiotic therapy has been established as the standard of care in patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma, much less is known about the value of antibiotic therapy in nongastrointestinal (non-GI) MALT lymphomas. A computerized search (Medline) accompanied by a manual search to identify clinical reports on the topic of antibacterial therapy in patients with non-GI MALT lymphomas was performed. The majority of data were available for MALT lymphoma of the ocular adnexa (OAML) including a total of 131 patients in 4 retrospective studies, 3 prospective series (including 81 patients), and 1 case report. Treatment was exclusively targeting Chlamydophila psittaci (CP), using doxycycline in all but 2 studies. The median follow-up for these studies was 25 months, and both CP-positive as well as CP-negative patients responded. Complete remission was achieved in 23 patients (18%), 36 (27%) had a partial remission, 55 (42%) had stable disease, and 8 patients (6%) had progressive disease accounting for an overall response rate of 45%. In the largest study, a better response was suggested in CP-positive patients. By contrast, only scattered reports could be found for other non-GI localizations, allowing no conclusion about the benefit of antibiotic therapy and probably resulting in a publication bias toward positive cases. Based on these results, antibiotic therapy using doxycycline appears to be a reasonable first-line therapy for patients with OAML. Antibiotics, however, remain experimental for the time being in patients with other non-GI MALT lymphomas. Further preclinical studies as well as large-scale therapeutic trials are warranted to define the role of antibiotic therapy in such patients.

Download Full-text